Clinical trials: Moderate to Severe Atopic Dermatitis, active
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADorable-1 (NCT05559359)
- Testing
- Lebrikizumab, Topical Corticosteroid (TCS)
- Where
- 85 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
- Trial name
- NCT07544862
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Atopic Dermatitis
A Study of TAVO101 in Atopic Dermatitis Patients
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
- Trial name
- NCT06176040
- Testing
- TAVO101
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Tavotek Biotherapeutics
Atopic Dermatitis
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- UP-TAINED (NCT05139836)
- Where
- 125 sites in Germany
- Volunteers
- 634 people
- Sponsor
- AbbVie
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Health Adult Subjects, Moderate-to-Severe Atopic Dermatitis
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07801612
- Testing
- HXN5003
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Atopic Dermatitis
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06884891
- Testing
- QL2108 injection, Dupixent®
- Volunteers
- 520 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
- Trial name
- NCT05509023
- Testing
- ADX-914
- Where
- 24 sites in United States
- Volunteers
- 102 people
- Sponsor
- Q32 Bio Inc.
Adolescents With Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07309055
- Testing
- SHR-1819 Injection
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Atopic Dermatitis
Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe Atopic Dermatitis.
This multicenter, randomized, double-blind, placebo-controlled will be conducted at Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine; Seventh People's Hospital, Shanghai University of…
- Trial name
- NCT06463353
- Testing
- trilinolein cream group, cream base group
- Volunteers
- 376 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss…
- Trial name
- PELISTAD-EX2 (NCT05983068)
- Testing
- dupilumab
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sanofi
Atopic Dermatitis
Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis
This study used a multicentre parallel three-armed randomised sham-controlled clinical trial methodology in order to objectively and normatively assess the efficacy of acupuncture on Quchi the Sea of Blood the Foot Sanli and the…
- Trial name
- NCT06922565
- Testing
- acupuncture
- Volunteers
- 110 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Atopic Dermatitis
Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in patients aged 12 years and older with moderate-to-severe atopic dermatitis All participants, both male and…
- Trial name
- ROFLU-AD12 (NCT07297602)
- Testing
- Oral roflumilast
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Nora Mohamed Abdelrazik
Atopic Dermatitis
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07220577
- Testing
- GIA632
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT06775860
- Testing
- ICP-332 Tablets
- Where
- 62 sites in China
- Volunteers
- 552 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Moderate-to-severe Atopic Dermatitis
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07344051
- Testing
- QLS12010
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis, Sleep Disturbance
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
- Trial name
- NCT05042258
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
- Trial name
- PossibILity (NCT07277660)
- Testing
- Galvokimig
- Where
- 59 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL